Are We Approaching a Biosimilars Boom?

Figure 1: A timeline snapshot of the next 6 years, indicating the major patents of the blockbuster drugs that are due to expire during this timeframe.
Figure 1: A timeline snapshot of the next 6 years, indicating the major patents of the blockbuster drugs that are due to expire during this timeframe.

This is one of the reasons why we have observed an upward trajectory of emerging biosimilar therapeutics, with no indication of a plateau in sight. Controversies are starting to circle around patent thickets and the manufacturers’ roles in driving high drug prices and limiting access to affordable medicines. Ethical investors are now focussing on transparency and accountability, calling for fair prices and broader patient access to essential medications. These are the defining factors that give biosimilars the opportune niche in an otherwise saturated market.

bps

Let’s take AbbVie’s Humira as an example, a drug which has over 100 patents associated with it. Sandoz gained FDA and EMA approval for their Hyrimoz HCF biosimilar in March 2023, quickly followed by product launches in July and November 2023 in US and EU respectively. In the US, a major pharmacy supplier brokered a deal with Sandoz to commercialise and launch a privately labelled Hyrimoz-HCF biosimilar which was priced 80% cheaper than the innovator drug. 

unnamed

Talk to our Biosimilar experts today